 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...210211212213214215216217218219220...235236» |
- | floxuridine / Generic mfg.
Phase classification, Enrollment change, Trial primary completion date: A Study of Systemic Chemotherapy With/Without HAI in Patients With Initially Unresectable Colorectal Liver Metastasis (clinicaltrials.gov) - Jan 28, 2015
P3, N=142, Recruiting, Sponsor: Yuhong Li
Phase classification: P2 --> P3 | N=71 --> 142 | Trial primary completion date: Dec 2018 --> Aug 2020
- ||| Avastin (bevacizumab) / Roche
Enrollment closed, Trial primary completion date, Metastases: STEAM: Sequential and Concurrent FOLFOXIRI/Bevacizumab Regimens Versus FOLFOX/Bevacizumab in First-Line Metastatic Colorectal Cancer (clinicaltrials.gov) - Jan 28, 2015
P2, N=280, Active, not recruiting, Sponsor: Hoffmann-La Roche
Phase classification: P2 --> P3 | N=71 --> 142 | Trial primary completion date: Dec 2018 --> Aug 2020 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2017 --> Dec 2016
- |||| Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Trial completion, Enrollment change, Trial primary completion date, Metastases: A Study of Neoadjuvant Chemoradiotherapy With 5-FU/Leucovorin (FL) vs. TS-1/Irinotecan in Patients With Locally Advanced Rectal Cancer (clinicaltrials.gov) - Jan 28, 2015
P2, N=136, Completed, Sponsor: Yonsei University
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2017 --> Dec 2016 Recruiting --> Completed | N=78 --> 136 | Trial primary completion date: Feb 2017 --> Sep 2014
- || Inlyta (axitinib) / Pfizer
Trial primary completion date, Metastases: A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov) - Jan 26, 2015
P2, N=70, Active, not recruiting, Sponsor: SCRI Development Innovations, LLC
Recruiting --> Completed | N=78 --> 136 | Trial primary completion date: Feb 2017 --> Sep 2014 Trial primary completion date: Jan 2015 --> Dec 2015
- oxaliplatin / Generic mfg., irinotecan / Generic mfg.
New P2 trial: Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study (clinicaltrials.gov) - Jan 26, 2015
P2, N=32, Not yet recruiting, Sponsor: Case Comprehensive Cancer Center
- 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
New P2 trial, Combination therapy: Hepatic Arterial Infusion With FOLFOX Alone or in Combination With IV Chemotherapy in Colon Cancer With Liver Metastasis (clinicaltrials.gov) - Jan 26, 2015
P2, N=0, Withdrawn, Sponsor: Western Regional Medical Center
- ||||| AMG 337 / ImmunityBio, Amgen
New P1/2 trial, Metastases: C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer (clinicaltrials.gov) - Jan 26, 2015
P1/2, N=308, Not yet recruiting, Sponsor: Eastern Cooperative Oncology Group
- ipatasertib (RG7440) / Roche
Enrollment closed, Combination therapy, Metastases: A Study of Ipatasertib (GDC-0068) in Combination With Fluoropyrimidine Plus Oxaliplatin in Participants With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer (clinicaltrials.gov) - Jan 26, 2015
P2, N=137, Active, not recruiting, Sponsor: Genentech, Inc.
Trial primary completion date: Jan 2015 --> Dec 2015 Recruiting --> Active, not recruiting
- || Erbitux (cetuximab) / Eli Lilly
Trial primary completion date, Metastases: Nordic 8 - A Phase II Trial (clinicaltrials.gov) - Jan 22, 2015
P2, N=180, Recruiting, Sponsor: Per Pfeiffer
Recruiting --> Active, not recruiting Trial primary completion date: Sep 2014 --> Dec 2016
- veliparib (ABT-888) / AbbVie
Enrollment closed, Combination therapy: A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors (clinicaltrials.gov) - Jan 22, 2015
P1, N=48, Active, not recruiting, Sponsor: AbbVie
Trial primary completion date: Sep 2014 --> Dec 2016 Enrolling by invitation --> Active, not recruiting
- ||| veliparib (ABT-888) / AbbVie
Trial completion, Combination therapy, Metastases: Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor (clinicaltrials.gov) - Jan 22, 2015
P1, N=60, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Enrolling by invitation --> Active, not recruiting Active, not recruiting --> Completed
- Stivarga (regorafenib) / Bayer
Trial primary completion date, Metastases: FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer (clinicaltrials.gov) - Jan 20, 2015
P2, N=36, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Completed Trial primary completion date: Jul 2015 --> Jul 2016
- ||||| Zaltrap (ziv-aflibercept IV) / Sanofi
New P2 trial, Metastases: RIA: Induction FOLFOX With or Without Aflibercept Followed by Chemoradiation in High Risk Locally Advanced Rectal Cancer (clinicaltrials.gov) - Jan 20, 2015
P2, N=180, Not yet recruiting, Sponsor: Grupo Espanol Multidisciplinario del Cancer Digestivo
- Avastin (bevacizumab) / Roche
Trial primary completion date, Combination therapy, Metastases: Sorafenib Tosylate, Bevacizumab, Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Jan 15, 2015
P1, N=18, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jul 2015 --> Jul 2016 Trial primary completion date: Dec 2014 --> Mar 2015
- || Avastin (bevacizumab) / Roche
New P3 trial, Metastases: TRIBE2: Folfoxiri Plus Bev Followed by Reintroduction of Folfoxiri Plus Bev at Progression Versus Folfox Plus Bev Followed by Folfiri Plus Bev in mCRC (clinicaltrials.gov) - Jan 15, 2015
P3, N=654, Not yet recruiting, Sponsor: Gruppo Oncologico del Nord-Ovest
- ||||| Vectibix (panitumumab) / Amgen
New P2 trial: SAPPHIRE: Safety and Efficacy Study of mFOLFOX6 + Panitumumab Combination Therapy and 5-FU/LV + Panitumumab Combination Therapy in Participants With Chemotherapy-na (clinicaltrials.gov) - Jan 15, 2015
P2, N=100, Recruiting, Sponsor: Takeda
- |||||| 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Enrollment open, Metastases: Rectal Cancer, Adjuvant Chemotherapy, FOLFOX(5-fluorouracil/Leucovorin/Oxaliplatin), Total Mesorectal Excision (clinicaltrials.gov) - Jan 15, 2015
P3, N=580, Recruiting, Sponsor: Yonsei University
Trial primary completion date: Dec 2014 --> Mar 2015 Not yet recruiting --> Recruiting
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
Enrollment open, Combination therapy, Metastases: REGAIN: Rechallenge of Cetuximab Combined With Irinotecan as Third-line Chemotherapy in Patients With Metastatic Colorectal Cancer - Phase II Study (clinicaltrials.gov) - Jan 14, 2015
P2, N=60, Recruiting, Sponsor: Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- LY2090314 / Eli Lilly
Trial primary completion date, Metastases, Biopsy: A Study of LY2090314 and Chemotherapy in Participants With Metastatic Pancreatic Cancer (clinicaltrials.gov) - Jan 13, 2015
P1/2, N=40, Recruiting, Sponsor: Eli Lilly and Company
Not yet recruiting --> Recruiting Trial primary completion date: May 2017 --> Dec 2019
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Trial primary completion date, Metastases: IriGen: Individualization of Dosage of Irinotecan in the FOLFIRI According to the Genetic Polymorphism of UGT1A1 in the First Line Treatment of Metastatic Colorectal Cancer (clinicaltrials.gov) - Jan 9, 2015
P2, N=47, Recruiting, Sponsor: Centre Jean Perrin
Trial primary completion date: May 2017 --> Dec 2019 Trial primary completion date: Dec 2014 --> Jun 2015
- || Kevzara (sarilumab) / Asahi Kasei, Regeneron, Sanofi
Trial primary completion date: SARILNIUSATURN: Phase II Study to Analyze Sarilumab in Non-Infectious Uveitis (clinicaltrials.gov) - Jan 9, 2015
P2, N=57, Recruiting, Sponsor: Sanofi
Trial primary completion date: Dec 2014 --> Jun 2015 Trial primary completion date: Sep 2016 --> Dec 2015
- Trial primary completion date, Metastases: Phase II Study of 5-FU, Oxaliplatin Plus Dasatinib in Metastatic Pancreatic Adenocarcinoma (clinicaltrials.gov) - Jan 9, 2015
P2, N=42, Recruiting, Sponsor: University of Florida
Trial primary completion date: Sep 2016 --> Dec 2015 Trial primary completion date: Dec 2015 --> Jun 2016
- Avastin (bevacizumab) / Roche
Enrollment change, Trial termination, Trial primary completion date, Surgery, Metastases: Combination Chemotherapy and Bevacizumab Before Surgery and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Jan 9, 2015
P2, N=1, Terminated, Sponsor: City of Hope Medical Center
Trial primary completion date: Dec 2015 --> Jun 2016 N=25 --> 1 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2017 --> Dec 2014; Slow accrual.
- ||||| enoxaparin sodium / Generic mfg.
Enrollment change: Chemotherapy With or Without Enoxaparin in Pancreatic Cancer (clinicaltrials.gov) - Jan 8, 2015
P2/3, N=312, Completed, Sponsor: CONKO-Studiengruppe
N=25 --> 1 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2017 --> Dec 2014; Slow accrual. N=540 --> 312
- 5-fluorouracil / Generic mfg.
Enrollment open, Metastases: Phase I Study of Neoadjuvant Radiotherapy With 5-Fluorouracil for Rectal Cancer (clinicaltrials.gov) - Jan 8, 2015
P1, N=20, Enrolling by invitation, Sponsor: Virginia Commonwealth University
N=540 --> 312 Not yet recruiting --> Enrolling by invitation
- | New P1/2 trial, Metastases: Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer (clinicaltrials.gov) - Jan 7, 2015
P1/2, N=51, Recruiting, Sponsor: University of Chicago
- | Zaltrap (ziv-aflibercept IV) / Sanofi
Trial completion, Combination therapy, Metastases: A Phase I Study of Aflibercept Plus FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) in Chinese Patients With Advanced Solid Malignancies (clinicaltrials.gov) - Jan 7, 2015
P1, N=20, Completed, Sponsor: Sanofi
Not yet recruiting --> Enrolling by invitation Active, not recruiting --> Completed
- || Erbitux (cetuximab) / Eli Lilly
Trial primary completion date, Metastases: FOLFOX Chemotherapy Regimen (5-FU, Leucovorin, Oxaliplatin) in Metastatic Colorectal Cancer (clinicaltrials.gov) - Jan 6, 2015
P1, N=83, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Trial primary completion date: Apr 2015 --> Apr 2016
- sunitinib / Generic mfg.
Enrollment change, Metastases: Sunitinib, Irinotecan, Fluorouracil, and Leucovorin In Treating Patients With Advanced Stomach Cancer or Gastroesophageal Cancer (clinicaltrials.gov) - Jan 6, 2015
P1, N=23, Active, not recruiting, Sponsor: Roswell Park Cancer Institute
Trial primary completion date: Apr 2015 --> Apr 2016 N=30 --> 23
- || oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg., fluorouracil topical / Generic mfg.
Trial primary completion date: Preoperative Chemo and Chemoradiotherapy for Adenocarcinoma of the Stomach and Gastroesophageal Junction (GEJ) (clinicaltrials.gov) - Jan 2, 2015
P2, N=58, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
N=30 --> 23 Trial primary completion date: Jan 2015 --> Jan 2017
- saridegib oral (IPI 926 oral) / Infinity Pharma
Enrollment open, Trial initiation date, Trial primary completion date, Metastases: FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma (clinicaltrials.gov) - Jan 2, 2015
P1, N=21, Recruiting, Sponsor: Andrew Ko
Trial primary completion date: Jan 2015 --> Jan 2017 Active, not recruiting --> Recruiting | Initiation date: Aug 2011 --> Nov 2014 | Trial primary completion date: Apr 2013 --> Nov 2017
- Trial primary completion date, Surgery, Metastases: Chemotherapy Followed by Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Head And Neck Cancer (clinicaltrials.gov) - Dec 30, 2014
P2, N=30, Active, not recruiting, Sponsor: City of Hope Medical Center
Active, not recruiting --> Recruiting | Initiation date: Aug 2011 --> Nov 2014 | Trial primary completion date: Apr 2013 --> Nov 2017 Trial primary completion date: Dec 2014 --> Dec 2015
- Avastin (bevacizumab) / Roche
Enrollment open, Metastases: Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer (clinicaltrials.gov) - Dec 30, 2014
P2, N=100, Recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
Trial primary completion date: Dec 2014 --> Dec 2015 Not yet recruiting --> Recruiting
- || Avastin (bevacizumab) / Roche
Trial primary completion date, Metastases: Bevacizumab Plus Modified FOLFOX6 Regimen as the Salvage Treatment in Metastatic Breast Cancer (MBC) Patients (clinicaltrials.gov) - Dec 29, 2014
P2, N=72, Active, not recruiting, Sponsor: Fudan University
Not yet recruiting --> Recruiting Trial primary completion date: Aug 2014 --> Mar 2015
- || Vectibix (panitumumab) / Amgen
Trial primary completion date: Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer (clinicaltrials.gov) - Dec 29, 2014
P2, N=78, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Trial primary completion date: Aug 2014 --> Mar 2015 Trial primary completion date: Mar 2015 --> Mar 2016
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Enrollment open, Combination therapy, Metastases: Efficacy and Safety of Aflibercept in Combination With FOLFIRI Chemotherapy as 1st Line Treatment for Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Dec 25, 2014
P2, N=54, Recruiting, Sponsor: Federation Francophone de Cancerologie Digestive
Trial primary completion date: Mar 2015 --> Mar 2016 Not yet recruiting --> Recruiting
- oxaliplatin / Generic mfg., irinotecan / Generic mfg., capecitabine / Generic mfg.
Trial primary completion date: Neoadjuvant Folfirinox Followed by Capecitabine and Limited Field Radiation for Localized Pancreatic Head Adenocarcinoma (clinicaltrials.gov) - Dec 24, 2014
P2, N=30, Recruiting, Sponsor: Medical University of South Carolina
Not yet recruiting --> Recruiting Trial primary completion date: Sep 2014 --> Sep 2015
- || dexamethasone / Generic mfg., floxuridine / Generic mfg.
Trial primary completion date, Combination therapy: Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combined With Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver (clinicaltrials.gov) - Dec 24, 2014
P2, N=64, Active, not recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Trial primary completion date: Sep 2014 --> Sep 2015 Trial primary completion date: May 2014 --> May 2015
- ||| Biomarker, Enrollment change, MSi-H Biomarker, PD(L)-1 Biomarker: MODUL: A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov) - Dec 24, 2014
P2, N=610, Not yet recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: May 2014 --> May 2015 N=1680 --> 610
- ||| dilpacimab (ABT-165) / AbbVie
Enrollment open, Metastases: A Study of ABT-165 in Subjects With Solid Tumors (clinicaltrials.gov) - Dec 24, 2014
P1, N=75, Recruiting, Sponsor: AbbVie
N=1680 --> 610 Suspended --> Recruiting
- GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells) / Novartis
Enrollment closed, Tumor cell: Pancreatic Tumor Cell Vaccine (GVAX), Cyclophosphamide, SBRT, and FOLFIRINOX in Patients With Resected Adenocarcinoma of the Pancreas (clinicaltrials.gov) - Dec 24, 2014
P=N/A, N=18, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Suspended --> Recruiting Recruiting --> Active, not recruiting
- leucovorin calcium / Generic mfg., cisplatin / Generic mfg., gemcitabine / Generic mfg.
Trial primary completion date, Metastases: Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant (clinicaltrials.gov) - Dec 19, 2014
P2, N=46, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting Trial primary completion date: Feb 2015 --> Feb 2017
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Enrollment change, Trial withdrawal, Trial primary completion date: Phase II Trial of Preoperative High-dose-rate Endorectal Brachytherapy and FOLFOX Chemotherapy for Rectal Cancer (clinicaltrials.gov) - Dec 19, 2014
P2, N=0, Withdrawn, Sponsor: Beth Israel Medical Center
Trial primary completion date: Feb 2015 --> Feb 2017 N=40 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Jun 2016 --> Nov 2014
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
New P2 trial: GCC 1314: Pelvic Radiotherapy With Concurrent Neoadjuvant FOLFOX for Patients With Newly Diagnosed Rectal Adenocarcinoma (clinicaltrials.gov) - Dec 19, 2014
P2, N=30, Not yet recruiting, Sponsor: University of Maryland
- alisertib (MLN8237) / Puma
New P1 trial, Combination therapy: Alisertib and Combination Chemotherapy in Treating Patients With Gastrointestinal Tumors (clinicaltrials.gov) - Dec 19, 2014
P1, N=30, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- |||| Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Enrollment open, Metastases: MATEO: Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer (clinicaltrials.gov) - Dec 19, 2014
P2, N=400, Recruiting, Sponsor: AIO-Studien-gGmbH
N=40 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Jun 2016 --> Nov 2014 Not yet recruiting --> Recruiting
- | Blincyto (blinatumomab) / Astellas, Amgen
P3 data: AALL1331: Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Dec 19, 2014
P3, N=598, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | N=438 --> 598 | Initiation date: Apr 2014 --> Dec 2014
- Hepacid (pegargiminase) / Polaris Pharma
Enrollment open, Metastases: Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carcinoma (clinicaltrials.gov) - Dec 19, 2014
P1, N=22, Recruiting, Sponsor: Polaris Group
Not yet recruiting --> Recruiting | N=438 --> 598 | Initiation date: Apr 2014 --> Dec 2014 Not yet recruiting --> Recruiting
- || Avastin (bevacizumab) / Roche
Trial primary completion date, Metastases: STEAM: Sequential and Concurrent FOLFOXIRI/Bevacizumab Regimens Versus FOLFOX/Bevacizumab in First-Line Metastatic Colorectal Cancer (clinicaltrials.gov) - Dec 17, 2014
P2, N=280, Recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2016 --> Dec 2017
- alvocidib (DSP-2033) / Sumitomo Pharma
Trial primary completion date: Alvocidib and Oxaliplatin With or Without Fluorouracil and Leucovorin Calcium in Treating Patients With Relapsed or Refractory Germ Cell Tumors (clinicaltrials.gov) - Dec 17, 2014
P2, N=50, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2016 --> Dec 2017 Trial primary completion date: Jan 2015 --> Apr 2015